Cohance Lifesciences Receives USFDA VAI Classification for Pashamylaram Facility

Market snapshot: Cohance Lifesciences Limited has received an Establishment Inspection Report from the United States Food and Drug Administration for its Pashamylaram manufacturing unit in Hyderabad. The regulatory agency classified the audit outcome as Voluntary Action Indicated, formally closing the inspection.

Data Snapshot

• USFDA issued Establishment Inspection Report classifying Pashamylaram manufacturing facility as Voluntary Action Indicated, concluding the inspection.
• USFDA inspection at Jaggaiahpet API facility concluded with 5 Form 483 observations in September 2026.
• USFDA inspection at Shamshabad formulation plant concluded with 4 Form 483 observations in September 2026.

Key Takeaways

• The USFDA has officially concluded its inspection of Cohance Lifesciences' Pashamylaram facility.
• The inspection outcome is classified as Voluntary Action Indicated (VAI), avoiding stricter regulatory actions such as Official Action Indicated (OAI) or warning letters.
• With receipt of the Establishment Inspection Report (EIR), regulatory uncertainty surrounding this specific facility stands resolved.

SAHI Perspective

A Voluntary Action Indicated (VAI) classification indicates that while objectionable conditions were observed during audit, the regulatory agency does not require administrative or regulatory sanction. This outcome allows uninterrupted commercial supply operations from the Pashamylaram facility.

Market Implications

Regulatory clearance for key manufacturing units removes potential compliance overhangs for contract development and manufacturing organizations, supporting revenue continuity for active pharmaceutical ingredient exports.

Trading Signals

Market Bias: Bullish

The issuance of an EIR with VAI status removes regulatory overhang for the Pashamylaram facility, confirming inspection closure without escalation to Official Action Indicated.

Overweight: Pharmaceuticals, Contract Development and Manufacturing Organizations (CDMO)

Trigger Factors:

• Formal receipt of EIR with VAI status for Pashamylaram facility
• Resolution and CAPA submission updates for Jaggaiahpet and Shamshabad facility audits

Time Horizon: Near-term (0-3 months)

Industry Context

USFDA facility inspections assess current Good Manufacturing Practices (cGMP). Classifications range from No Action Indicated (NAI) to Voluntary Action Indicated (VAI) and Official Action Indicated (OAI). VAI reflects minor compliance items that do not disrupt facility operations.

Key Risks to Watch

• Ongoing CAPA commitments for Form 483 observations issued during September 2026 inspections at Jaggaiahpet and Shamshabad facilities.
• Potential timing delays in receiving final EIR clearances for other active manufacturing sites.

Recent Developments

In September 2026, Cohance Lifesciences completed USFDA audits at its Jaggaiahpet API manufacturing unit and Shamshabad formulation facility, receiving 5 and 4 Form 483 observations respectively.

Closing Insight

Securing a VAI classification and formal inspection closure for the Pashamylaram unit provides operational stability and maintains client confidence in Cohance's manufacturing standards.

High Performance Trading with SAHI.